Eric D Lynch

Summary

Publications

  1. ncbi request reprint Ebselen-mediated protection from single and repeated noise exposure in rat
    Eric D Lynch
    Sound Pharmaceuticals, Inc, Seattle, WA 98103, USA
    Laryngoscope 114:333-7. 2004
  2. ncbi request reprint Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity
    Eric D Lynch
    Sound Pharmaceuticals, Inc, Seattle, WA, USA
    Anticancer Drugs 16:569-79. 2005
  3. ncbi request reprint Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen
    Eric D Lynch
    Sound Pharmaceuticals, Inc, Research and Development, 4010 Stone Way N, Suite 120, Seattle, WA 98103, USA
    Hear Res 201:81-9. 2005
  4. ncbi request reprint Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase
    Jonathan Kil
    Sound Pharmaceuticals, Inc, Research and Development, 4010 Stone Way N Suite 120, Seattle, WA 98103, USA
    Hear Res 226:44-51. 2007
  5. ncbi request reprint Compounds for the prevention and treatment of noise-induced hearing loss
    Eric D Lynch
    4010 Stone Way N, Suite 120, Seattle, WA 98103, USA
    Drug Discov Today 10:1291-8. 2005
  6. pmc Mutations in a novel isoform of TRIOBP that encodes a filamentous-actin binding protein are responsible for DFNB28 recessive nonsyndromic hearing loss
    Hashem Shahin
    Department of Life Sciences, Bethlehem University, Bethlehem
    Am J Hum Genet 78:144-52. 2006

Collaborators

  • Jonathan Kil
  • K B Avraham
  • Hashem Shahin
  • Mary Claire King
  • Judeh Abu Sa'ed
  • Amal Abu Rayan
  • Tama Sobe
  • Ming K Lee
  • Tom Walsh
  • Moein Kanaan

Detail Information

Publications6

  1. ncbi request reprint Ebselen-mediated protection from single and repeated noise exposure in rat
    Eric D Lynch
    Sound Pharmaceuticals, Inc, Seattle, WA 98103, USA
    Laryngoscope 114:333-7. 2004
    ..Ebselen, a glutathione peroxidase mimic, is a candidate compound for the prevention of noise-induced hearing loss...
  2. ncbi request reprint Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity
    Eric D Lynch
    Sound Pharmaceuticals, Inc, Seattle, WA, USA
    Anticancer Drugs 16:569-79. 2005
    ..On the contrary, improved mortality, morbidity and outcome were observed in the ovarian cancer model. This combined oral formulation of ebselen and allopurinol is an attractive candidate for clinical evaluation...
  3. ncbi request reprint Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen
    Eric D Lynch
    Sound Pharmaceuticals, Inc, Research and Development, 4010 Stone Way N, Suite 120, Seattle, WA 98103, USA
    Hear Res 201:81-9. 2005
    ..Further evaluation of the chemoprotective effects of ebselen and allopurinol on cisplatin side effects in the presence of tumor appears warranted...
  4. ncbi request reprint Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase
    Jonathan Kil
    Sound Pharmaceuticals, Inc, Research and Development, 4010 Stone Way N Suite 120, Seattle, WA 98103, USA
    Hear Res 226:44-51. 2007
    ..This latter mechanism may be due to the preservation of endogenous GPx1 from ROS/RNS induced degradation and/or the stimulation of GPx1 expression or activity...
  5. ncbi request reprint Compounds for the prevention and treatment of noise-induced hearing loss
    Eric D Lynch
    4010 Stone Way N, Suite 120, Seattle, WA 98103, USA
    Drug Discov Today 10:1291-8. 2005
    ..This review covers strategies that are under investigation for NIHL. Drugs that effectively prevent and treat NIHL will have a significant impact on medical costs, disability compensation and several issues affecting the quality of life...
  6. pmc Mutations in a novel isoform of TRIOBP that encodes a filamentous-actin binding protein are responsible for DFNB28 recessive nonsyndromic hearing loss
    Hashem Shahin
    Department of Life Sciences, Bethlehem University, Bethlehem
    Am J Hum Genet 78:144-52. 2006
    ..Antibodies to TRIOBP reveal expression in sensory cells of the inner ear and colocalization with F-actin along the length of the stereocilia...